Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

BUFFALO, N.Y. — In January, Nicole Albanese, PharmD, clinical associate professor of pharmacy practice in the University at ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

The Centres for Medicare and Medicaid Services (CMS) said late on Friday that it would not cover anti-obesity medicines (AOMs) like Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

It could have huge implications for drugmakers, patients and Medicare's spending on prescription ... they all share the same active ingredient, semaglutide. Without the so-called pill penalty ...

Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

Pennsylvania doctor Neil Anand, MD, was convicted for illegally doling out "goody bags" of prescription drugs that patients ...

Ozempic is not marketed as a weight loss drug and is prescribed to those with type 2 diabetes to help manage their condition ...